References
- Duray MC, Marchand E, Gohy S, et al. Granulomatous meningitis due to rheumatoid arthritis. Acta Neurol Belg. 2012 Jun;112(2):193–197.10.1007/s13760-012-0021-5
- Servioli MJ, Chugh C, Lee JM, et al. Rheumatoid meningitis. Front Neurol. 2011 Dec;26(2):84.
- Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275–2285.10.1001/jama.295.19.2275
- Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014 Mar;73(3):529–535.10.1136/annrheumdis-2013-204575
- Kourbeti IS, Ziakas PD, Mylonakis E. Biological therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Inf Dis. 2014 Jun;58(12):1649–1657.10.1093/cid/ciu185
- Singh JA, Cameron C, Noorbaloochi S et al. Risk of serious infection in biological treatments of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015 Jul 18;386(9990):258–265.10.1016/S0140-6736(14)61704-9
- Scrivo R, Armignacco O. Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data. Int J Rheum Dis. 2014 Sep;17(7):716–724.10.1111/1756-185X.12375
- Daïen CI, Monnier A, Claudepierre P. Sarcoïd like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. 2009 Aug;48(8):883–886.10.1093/rheumatology/kep046
- Hegde N, Gayomali C, Rich MW. Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum? South Med J. 2005 May;98(5):564–566.10.1097/01.SMJ.0000155499.21189.75
- Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet. 2001 Nov;358(9295):1784.10.1016/S0140-6736(01)06810-6
- Cohen JD, Jorgensen C, Sany J. Leflunomide-induced aseptic meningitis. Joint Bone Spine. 2003 May;71(3):243–245.
- Guadalupe Loya-de la Cerda D, Avilés-Solís JC, Delgado-Montemayor MJ, et al. Isolated rheumatoid arthritis-associated cerebral vasculitis: a diagnostic challenge. Joint Bone Spine. 2013 Jan;80(1):88–90.10.1016/j.jbspin.2012.06.014
- Glace B, Gottenberg JE, Mariette X, et al. Efficacy of rituximab on pulmonary nodules: findings in 10 patients from the French AIR/PR Registry. Ann Rheum Dis. 2012 Aug;71(8):1429–1431.10.1136/annrheumdis-2011-200915
- Puéchal X, Gottenberg JE, Berthelot JM, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: result from the AutoImmunity and Rituximab Registry. Arthritis Care Res. 2012 Mar;64(3):331–339.
- Highton J, Hung N, Hessian P, et al. Pulmonary rheumatoid nodules demonstrating features usually associated with rheumatoid synovial membrane. Rheumatology. 2007 May;46(5):811–814.10.1093/rheumatology/kel411
- Edwards JC, Szczepański L, Szechiński J et al. Efficacy of B-Cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Eng J Med. 2004 Jun17;350(25):2572–2581.10.1056/NEJMoa032534
- Golay J, Semenzato G, Rambaldi A et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013 Nov–Dec;5(6):826–837.10.4161/mabs.26008